DOCSLIB.ORG

Combined Action of C-Kit and Erythropoietin on Erythroid Progenitor Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Action of C-Kit and Erythropoietin on Erythroid Progenitor Cells Development 114, 245-252 (1992) 245 Printed in Great Britain © The Company of Biologists Limited 1992 Combined action of c-Kit and erythropoietin on erythroid progenitor cells OSAMU OHNEDA, NOBUAKI YANAI and MASUO OBINATA* Department of Cell Biology, The Research Institute for Tuberculosis and Cancer, Tohoku University, Seiryo-machi 4-1, Aoba-ku, Sendai 980, Japan *Author for correspondence Summary Mutations at the murine dominant-white spotting locus effective only at the early phase (within 6 hours after (WO (c-lrii) affect various aspects of hematopoiesis. We erythropoietin addition) before the cells start to prolifer- have made antibodies against c-Kit with the synthetic ate induced by erythropoietin. During the early phase, peptides deduced from the murine c-kil gene and erythropoietin down-regulated c-kit gene expression. examined the role of c-Kit in erythropoiesis. The These results suggest a mechanism of combined action of antibody inhibited the stromal cell-dependent large c-Kit with erythropoietin on the lineage-restricted colony formation of the erythroid progenitors. In the erythroid progenitor cells. culture of erythropoietin-responsive erythroid progeni- tors of the anemia-inducing Friend virus-infected mouse spleen, the antibody inhibited only proliferation, but not Key words: c-Kit, erythroid progenitor cells, differentiation of the progenitor cells. The inhibition was erythropoietin, W mutation. Introduction expression was found to be depressed, presumably because of a reduction in c-M-expressing erythroid cell Mutations at the murine dominant-white spotting locus populations in the fetal liver, as a result of the mutation. (W) affect various aspects of hematopoiesis. The defect Whereas levels of the erythroid progenitor cells (CFU- exerted by W mutations is intrinsic to hematopoietic E) were markedly reduced, normal numbers of the cells and the hematopoietic microenvironment in these granulocyte-macrophage progenitor cells (CFU-GM) mice is unaffected and able to support hematopoiesis. were observed in the W/W fetal liver (Nocka et al., Recently, Chabot et al. (1988) have mapped the proto- 1989) consistent with earner observations of only minor oncogene c-kit to the W locus on mouse chromosome 5 effects on granulopoiesis in W mutant mice (Russell, and Geissler et al. (1988) subsequently showed that the 1979). c-kit gene is rearranged in two different W mutants. The Apparently, because of the different microenviron- c-kit gene encodes a transmembrane kinase similar to ments in fetal liver, adult spleen and bone marrow, W CSF-1R and PDGFR (Qui et al., 1988; Yarden et al., 3 mutations affect erythropoiesis to different degrees at 1987). A 145 xlO MT tyrosine-specific transmembrane different stages of differentiation in the various hemato- kinase has been identified and characterized in brain poietic organs. Thus, it is necessary to examine the tissue extracts and in human glioblastoma cell line direct role of c-Kit on the erythropoietic progenitor (Yarden et al., 1987). Recently, SCF or 5/ factor has cells in vitro. Recently, we have demonstrated the in been identified as a candidate for the ligand of the c-Kit vitro reconstruction of a microenvironment adequate protein (receptor) (Zsebo et al., 1990; Martin et al., for a rapid expansion of erythroid cells in fetal liver 1990; Huang et al., 1990; Williams et al., 1990; Flanagan using established fetal liver stromal cells (Ohneda et al., et al., 1990). This is consistent with an earlier conjecture 1990). In this work, we examined the role of c-Kit on that the W locus encodes a cell-surface receptor that the proliferation and differentiation of the late eryth- functions in cell-to-cell interactions during develop- roid progenitors from fetal livers on the supporting ment and hematopoiesis (Russell, 1979). Most W stromal cell layers and from the anemia-inducing Friend mutations cause macrocytic anemia and are known to virus-infected mouse spleens. affect the erythroid progenitors (Gregory and Eaves, 1978; Iscove, 1978; Russell, 1979). Expression of c-kit was found to concur with the sites of active erythropoi- Materials and methods esis in yolk sac (Orr-Urtreger et al., 1990), fetal liver, adult bone marrow, and in Friend virus-transformed Preparation of antibody to c-Kit peptides cell lines (Nocka et al., 1989). In addition, c-kit Two oligopeptides (KIT1; FKTYFNEMVENKKNEW, 246 O. Ohneda, N. Yanai and M. Obinata KIT2; AQVKHNSWHRGDFNYERQE) deduced from the Detection of genotypes of the littermates by RT-PCR murine c-kit gene sequence (Qui et al., 1988) were synthesized method by a peptide synthesizer (Applied Biosystems Inc.). Two The genotypes of the littermates obtained by the mating of rabbits were immunized by subcutaneous injection with 500 WB-W/+ x WB-W/+ were determined by reverse transcrip- /jg of the oligopeptides coupled with keyhole limpet hemocya- tase-polymerase chain reaction (RT-PCR). The primers used nin emulsified in Freund's complete adjuvant, followed by were sense primer (1541-1565 in nucleotide number); 5'- additional injections of 500 /ig of the oligopeptide coupled GCCITCTTTAACTTTGCATTTAAAG-3', and antisense with keyhole limpet hemocyanin emulsified in Freund's primer (2656-2637): 3'-CTTGGAGTCGACCGGCATCC-5' incomplete adjuvant after 2, 4 and 6 weeks. The antisera were and these primers were kindly supplied by Dr T. Kunisada of obtained and evaluated by ELISA 2 weeks after the final Kumamoto University Medical School, Kumamoto, Japan. booster. igG was precipitated with 1.34 volumes of saturated The amplified DNA product from the W mutant mRNA is ammonium sulphate and dialyzed against 10 mM sodium shorter than that of the wild-type mRNA as described by phosphate buffer (pH 8.0). The dialyzed materials were Hayashi et al. (1991V For cDNA synthesis, 10 \i% of RNAs applied to a DEAE cellulose column and the flow-through from brains (C57BL/6J-+/+ mouse and WB-W/+ mouse) and fractions were collected. Amounts of IgG in the flow-through from whole embryos (littermates of the mating of WB-W/+ x fractions were estimated by ELISA. W/+) were incubated with 100 pmol of random primer and 200 U of MMLV reverse transcriptase (BRL) in 20 /il reaction Immunoprecipitation and autophosphorylation of mixture containing 0.55 M Tris-HCl, pH 8.3, 0.075 M KC1, 3 c-Kit protein mM MgCk, 10 mM dithiothreitol, 200 mM deoxyribonucleo- tide triphosphates, and 20 U of RNAase inhibitor (Pharma- Immune complex kinase assay was performed essentially as cia) at 37°C for 60 minutes. The cDNA was amplified by 2.5 described previously (Majumder et al., 1988). Briefly, mouse units of Taq DNA polymerase and 40 pmol of sense and brain (400 mg) was homogenized in 2 ml of lysis buffer (50 antisense primers in 20 ml reaction buffer (10 mM Tris-HCl, mM Tris, 150 mM NaCl, 20 mM EDTA, 1% Triton X-100,1% pH 8.3, 50 mM KC1,1.5 mM MgCl2, 0.01% gelatin and 0.5 U deoxycholate, 1% SDS, 1 mM phenylmethylsulfonyl fluoride, of Perfect Match (Stratagene) for 28 cycles in a program 20 jig/ml leupeptin, lmM sodium vanadate at pH 8.4) and Temperature Control System PC 700 (Astec Inc.). The centrifuged at 100,000 g for 45 minutes. The supernatant was amplified DNA products were analyzed by 1.4% agarose gel subjected to wheat-germ-agglutinin chromatography and electrophoresis. pretreated with the non-immune serum. The pretreated materials were immunoprecipitated with KTT1 antibodies that were conjugated with protein A sepharose, and incubated Northern blot analysis of c-kit mRNA and SCF with [y- P]ATP. The labeled proteins were separated by mRNA SDS-PAGE and visualized by autoradiography. The erythroid progenitor cells derived from Friend virus- infected mice were cultured in vitro with 0.1 U/ml erythropoi- etin and the cells were collected at appropriate time intervals Preparation of hematopoietic progenitor cells and (0-12 hours). The cells were homogenized in guanidine coculture of hematopoietic cells on stromal cell layers isothiocyanate, and RNAs were isolated by centrifugation Preparation of hematopoietic progenitor cells and coculture through CsCl. 4 ng of poly (A)+ RNA, obtained by oligo(dT)- of hemopoietic cells on stromal cell layers were performed as Latex (Oligotex-dT30, Nihon Synthetic Rubber Co.), were described previously (Yanai et al., 1989). Hematopoietic separated in 0.7% agarose gel containing formaldehyde, and progenitor cells were prepared from the liver of 13-day transferred to nylon membranes. The membranes were embryos after mating of WB-W/+ x WB-W/+ mice. prehybridized and hybridized with the nick-translated 5.1 kb Hemopoietic progenitor cells were cultured on monolayers of c-kit cDNA (provided by Dr A. Singh, Genentech.Inc). The FLS5 and MSS62 cell lines in multiwell plates (Falcon 3047, amount of c-kit mRNA in each sample was assessed by Becton Dickinson), in Iscove's modified Dulbecco's medium comparison to hybridization with a ^3-actin probe. (IMDM; Gibco), supplemented with 0.4% methylcellulose, For detection of SCF mRNA in the stromal cells, total 30% heat-inactivated FBS, 1% bovine serum albumin, 100 RNAs were isolated from two stromal cell lines, FLS cell lines /JM 2-mercaptoethanol and erythropoietin (recombinant (Ohneda et al., 1990) and MSS cell lines (Yanai et al., 1989). human erythropoietin, generously supplied by Kirin-Amgen The SCF cDNA probe was prepared by reverse transcriptase- Co. Ltd.). After 4 days in culture, erythroid colonies were polymerase chain reaction (RT-PCR) from mRNA of FLS5 scored by direct staining with benzidine. cells with sense primer (16-36 nucleotide number by Zsebo et al., 1990) 5'-ATGAAGAAGACACAAACTTGG-3' and Isolation and culture of splenic erythroblasts antisense primer (598-579) 3'-ACGTCGGTCCGAGG- Anemia-inducing Friend virus (FVA, provided by Dr H. GAATCCT-5'. The sequence of the product of RT-PCR was confirmed after subcloning. Amanuma of RIKEN, The Institute of Physical and Chemical Research, Tsukuba, Japan) was injected intravenously into 6- week-old DBA/2 mice.
Load more

Recommended publications
  • Insights Into the Cellular Mechanisms of Erythropoietin-Thrombopoietin Synergy
    Papayannopoulou et al.: Epo and Tpo Synergy Experimental Hematology 24:660-669 (19961 661 @ 1996 International Society for Experimental Hematology Rapid Communication ulation with fluorescence microscopy. Purified subsets were grown in plasma clot and methylcellulose clonal cultures and in suspension cultures using the combinations of cytokines Insights into the cellular mechanisms cadaveric bone marrow cells obtained from Northwest described in the text. Single cells from the different subsets Center, Puget Sound Blood Bank (Seattle, WA), were were. also deposited (by FACS) on 96-well plates containing of erythropoietin-thrombopoietin synergy washed, and incubated overnight in IMDM with 10% medmm and cytokines. Clonal growth from single-cell wells calf serum on tissue culture plates to remove adherent were double-labeled with antiglycophorin A-PE and anti­ Thalia Papayannopoulou, Martha Brice, Denise Farrer, Kenneth Kaushansky From the nonadherent cells, CD34+ cells were isolated CD41- FITC between days 10 and 19. direct immunoadherence on anti-CD34 monoclonal anti­ University of Washington, Department of Medicine, Seattle, WA (mAb)-coated plates, as previously described [15]. Purity Immunocytochemistry Offprint requests to: Thalia Papayannopoulou, MD, DrSci, University of Washington, isolated CD34+ cells ranged from 80 to 96% by this For immunocytochemistry, either plasma clot or cytospin cell Division of Hematology, Box 357710, Seattle, WA 98195-7710 od. Peripheral blood CD34 + cells from granulocyte preparations were used. These were fixed at days 6-7 and (Received 24 January 1996; revised 14 February 1996; accepted 16 February 1996) ulating factor (G-CSF)-mobilized normal donors 12-13 with pH 6.5 Histochoice (Amresco, Solon, OH) and provided by Dr.
    [Show full text]
  • The Molecular Mechanisms That Control Thrombopoiesis
    The molecular mechanisms that control thrombopoiesis Kenneth Kaushansky J Clin Invest. 2005;115(12):3339-3347. https://doi.org/10.1172/JCI26674. Review Series Our understanding of thrombopoiesis — the formation of blood platelets — has improved greatly in the last decade, with the cloning and characterization of thrombopoietin, the primary regulator of this process. Thrombopoietin affects nearly all aspects of platelet production, from self-renewal and expansion of HSCs, through stimulation of the proliferation of megakaryocyte progenitor cells, to support of the maturation of these cells into platelet-producing cells. The molecular and cellular mechanisms through which thrombopoietin affects platelet production provide new insights into the interplay between intrinsic and extrinsic influences on hematopoiesis and highlight new opportunities to translate basic biology into clinical advances. Find the latest version: https://jci.me/26674/pdf Review series The molecular mechanisms that control thrombopoiesis Kenneth Kaushansky Department of Medicine, Division of Hematology/Oncology, University of California, San Diego, San Diego, California, USA. Our understanding of thrombopoiesis — the formation of blood platelets — has improved greatly in the last decade, with the cloning and characterization of thrombopoietin, the primary regulator of this process. Thrombopoietin affects nearly all aspects of platelet production, from self-renewal and expansion of HSCs, through stimulation of the proliferation of megakaryocyte progenitor cells, to support of the maturation of these cells into platelet-pro- ducing cells. The molecular and cellular mechanisms through which thrombopoietin affects platelet production provide new insights into the interplay between intrinsic and extrinsic influences on hematopoiesis and highlight new opportunities to translate basic biology into clinical advances.
    [Show full text]
  • Induction of Erythropoietin Increases the Cell Proliferation Rate in a Hypoxia‑Inducible Factor‑1‑Dependent and ‑Independent Manner in Renal Cell Carcinoma Cell Lines
    ONCOLOGY LETTERS 5: 1765-1770, 2013 Induction of erythropoietin increases the cell proliferation rate in a hypoxia‑inducible factor‑1‑dependent and ‑independent manner in renal cell carcinoma cell lines YUTAKA FUJISUE1, TAKATOSHI NAKAGAWA2, KIYOSHI TAKAHARA1, TERUO INAMOTO1, SATOSHI KIYAMA1, HARUHITO AZUMA1 and MICHIO ASAHI2 Departments of 1Urology and 2Pharmacology, Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan Received November 28, 2012; Accepted February 25, 2013 DOI: 10.3892/ol.2013.1283 Abstract. Erythropoietin (Epo) is a potent inducer of erythro- Introduction poiesis that is mainly produced in the kidney. Epo is expressed not only in the normal kidney, but also in renal cell carcinomas Erythropoietin (Epo) is a 30-kDa glycoprotein that functions (RCCs). The aim of the present study was to gain insights as an important cytokine in erythrocytes. Epo is usually into the roles of Epo and its receptor (EpoR) in RCC cells. produced by stromal cells of the adult kidney cortex or fetal The study used two RCC cell lines, Caki-1 and SKRC44, in liver and then released into the blood, with its production which Epo and EpoR are known to be highly expressed. The initially induced by hypoxia or hypotension (1-5). In the bone proliferation rate and expression level of hypoxia-inducible marrow, Epo binds to the erythropoietin receptor (EpoR) factor-1α (HIF-1α) were measured prior to and following expressed in erythroid progenitor cells or undifferentiated Epo treatment and under normoxic and hypoxic conditions. erythroblasts, which induces signal transduction mechanisms To examine whether HIF-1α or Epo were involved in cellular that protect the undifferentiated erythrocytes from apoptosis proliferation during hypoxia, these proteins were knocked and promote their proliferation and differentiation.
    [Show full text]
  • Targeted Erythropoietin Selectively Stimulates Red Blood Cell Expansion in Vivo
    Targeted erythropoietin selectively stimulates red blood cell expansion in vivo Devin R. Burrilla, Andyna Verneta, James J. Collinsa,b,c,d, Pamela A. Silvera,e,1, and Jeffrey C. Waya aWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115; bSynthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA 02139; cInstitute for Medical Engineering & Science, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; dBroad Institute of MIT and Harvard, Cambridge, MA 02139; and eDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115 Edited by Ronald A. DePinho, University of Texas MD Anderson Cancer Center, Houston, TX, and approved March 30, 2016 (received for review December 23, 2015) The design of cell-targeted protein therapeutics can be informed peptide linker that permits simultaneous binding of both elements by natural protein–protein interactions that use cooperative phys- to the same cell surface. The targeting element anchors the mu- ical contacts to achieve cell type specificity. Here we applied this tated activity element to the desired cell surface (Fig. 1A, Middle), approach in vivo to the anemia drug erythropoietin (EPO), to direct thereby creating a high local concentration and driving receptor its activity to EPO receptors (EPO-Rs) on red blood cell (RBC) pre- binding despite the mutation (Fig. 1A, Bottom). Off-target sig- cursors and prevent interaction with EPO-Rs on nonerythroid cells, naling should be minimal (Fig. 1B) and should decrease in pro- such as platelets. Our engineered EPO molecule was mutated to portion to the mutation strength. weaken its affinity for EPO-R, but its avidity for RBC precursors Here we tested the chimeric activator strategy in vivo using was rescued via tethering to an antibody fragment that specifi- erythropoietin (EPO) as the drug to be targeted.
    [Show full text]
  • And Insulin-Like Growth Factor-I (IGF-I) in Regulating Human Erythropoiesis
    Leukemia (1998) 12, 371–381 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions – comparison to other cytokines and growth factors J Ratajczak, Q Zhang, E Pertusini, BS Wojczyk, MA Wasik and MZ Ratajczak Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA The role of insulin (INS), and insulin-like growth factor-I (IGF- has been difficult to assess. The fact that EpO alone fails to I) in the regulation of human erythropoiesis is not completely stimulate BFU-E in serum-free conditions, but does do in understood. To address this issue we employed several comp- lementary strategies including: serum free cloning of CD34؉ serum containing cultures indicates that serum contains some cells, RT-PCR, FACS analysis, and mRNA perturbation with oli- crucial growth factors necessary for the BFU-E development. godeoxynucleotides (ODN). In a serum-free culture model, both In previous studies from our laboratory, we examined the ؉ INS and IGF-I enhanced survival of CD34 cells, but neither of role of IGF-I12 and KL9,11,13 in the regulation of early human these growth factors stimulated their proliferation. The influ- erythropoiesis. Both of these growth factors are considered to ence of INS and IGF-I on erythroid colony development was be crucial for the BFU-E growth.3,6,8,14 Unexpectedly, that dependent on a combination of growth factors used for stimul- + ating BFU-E growth.
    [Show full text]
  • Immunohistochemical Expression of Erythropoietin in Invasive Breast Carcinoma with Metastasis to Lymph Nodes
    Review and Research on Cancer Treatment Volume 4, Issue 1 (2018) ISSN 2544-2147 Immunohistochemical expression of erythropoietin in invasive breast carcinoma with metastasis to lymph nodes Maksimiuk M.* Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Sobiborowicz A. Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Sobieraj M. Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Liszcz A. Students' Scientific Organization at the Medical University of Warsaw, Oczki 1a, 02-007 Warsaw Sobol M. Department of Biophysics and Human Physiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw Patera J. Department of Pathomorphology, Military Institute of Health Services, Warsaw, Poland Badowska-Kozakiewicz A.M. Department of Biophysics and Human Physiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw *corresponding author: Marta Maksimiuk, Department of Biophysics and Human Physiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, [email protected], tel: 691 – 230 – 268 Abstract: Introduction: Tumor characteristics, such as size, lymph node status, histological type of the neoplasm and its grade, are well known prognostic factors in breast cancer. The ongoing search for new prognostic factors include Bcl2, Bax, Cox-2 or HIF1- alpha, which plays a key role in phenomenon of tumor hypoxia and might induce transcription of the EPO gene. Erythropoietin may influence lymph node metastasis or stimulate tumor progression, thus it seemed interesting to determine its expression in invasive breast cancers with lymph node metastases presenting different basic immunohistochemical profiles (ER, PR, HER2). Aim: To evaluate the relationship between histological grade, tumor size, lymph node status, expression of ER, PR, HER2 and immunohistochemical expression of erythropoietin in invasive breast cancer with metastasis to lymph nodes.
    [Show full text]
  • The Thrombopoietin Receptor : Revisiting the Master Regulator of Platelet Production
    This is a repository copy of The thrombopoietin receptor : revisiting the master regulator of platelet production. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/175234/ Version: Published Version Article: Hitchcock, Ian S orcid.org/0000-0001-7170-6703, Hafer, Maximillian, Sangkhae, Veena et al. (1 more author) (2021) The thrombopoietin receptor : revisiting the master regulator of platelet production. Platelets. pp. 1-9. ISSN 0953-7104 https://doi.org/10.1080/09537104.2021.1925102 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Platelets ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iplt20 The thrombopoietin receptor: revisiting the master regulator of platelet production Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker To cite this article: Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker (2021): The thrombopoietin receptor: revisiting the master regulator of platelet production, Platelets, DOI: 10.1080/09537104.2021.1925102 To link to this article: https://doi.org/10.1080/09537104.2021.1925102 © 2021 The Author(s).
    [Show full text]
  • As a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial
    cells Review Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine Asterios S. Tsiftsoglou Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; [email protected] Abstract: Human erythropoietin (EPO) is an N-linked glycoprotein consisting of 166 aa that is pro- duced in the kidney during the adult life and acts both as a peptide hormone and hematopoietic growth factor (HGF), stimulating bone marrow erythropoiesis. EPO production is activated by hypoxia and is regulated via an oxygen-sensitive feedback loop. EPO acts via its homodimeric erythropoietin receptor (EPO-R) that increases cell survival and drives the terminal erythroid mat- uration of progenitors BFU-Es and CFU-Es to billions of mature RBCs. This pathway involves the activation of multiple erythroid transcription factors, such as GATA1, FOG1, TAL-1, EKLF and BCL11A, and leads to the overexpression of genes encoding enzymes involved in heme biosynthesis Citation: Tsiftsoglou, A.S. and the production of hemoglobin. The detection of a heterodimeric complex of EPO-R (consist- Erythropoietin (EPO) as a Key ing of one EPO-R chain and the CSF2RB β-chain, CD131) in several tissues (brain, heart, skeletal Regulator of Erythropoiesis, Bone muscle) explains the EPO pleotropic action as a protection factor for several cells, including the Remodeling and Endothelial multipotent MSCs as well as cells modulating the innate and adaptive immunity arms. EPO induces Transdifferentiation of Multipotent the osteogenic and endothelial transdifferentiation of the multipotent MSCs via the activation of Mesenchymal Stem Cells (MSCs): EPO-R signaling pathways, leading to bone remodeling, induction of angiogenesis and secretion Implications in Regenerative of a large number of trophic factors (secretome).
    [Show full text]
  • Correlation with Vasculogenic Mimicry and Poor Prognosis
    Int J Clin Exp Pathol 2015;8(4):4033-4043 www.ijcep.com /ISSN:1936-2625/IJCEP0006586 Original Article Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis Zhihong Yang1,2*, Baocun Sun1,2,3*, Xiulan Zhao1,2*, Bing Shao1, Jindan An1, Qiang Gu1,2, Yong Wang1, Xueyi Dong1, Yanhui Zhang1,3, Zhiqiang Qiu1,3 1Department of Pathology, Tianjin Medical University, Tianjin 300070, China; 2Department of Pathology, General Hospital of Tianjin Medical University, Tianjin 300052, China; 3Department of Pathology, Cancer Hospital of Tianjin Medical University, Tianjin 300060, China. *Equal contributors. Received February 1, 2015; Accepted March 30, 2015; Epub April 1, 2015; Published April 15, 2015 Abstract: To evaluate erythropoietin (Epo) and erythropoietin receptor (EpoR) expression, its relationship with vas- culogenic mimicry (VM) and its prognostic value in human hepatocellular carcinoma (HCC), we examined Epo/EpoR expression and VM formation using immunohistochemistry and CD31/PAS (periodic acid-Schiff) double staining on 92 HCC specimens. The correlation between Epo/EpoR expression and VM formation was analyzed using two-tailed Chi-square test and Spearman correlation analysis. Survival curves were generated using Kaplan-Meier method. Multivariate analysis was performed using Cox regression model to assess the prognostic values. Results showed positive correlation between Epo/EpoR expression and VM formation (P < 0.05). Patients with Epo or EpoR expres- sion exhibited poorer overall survival (OS) than Epo-negative or EpoR-negative patients (P < 0.05). Epo-positive/VM- positive and EpoR-positive/VM-positive patients had the worst OS (P < 0.05). In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to OS.
    [Show full text]
  • Erythropoietin Prevents Haloperidol Treatment-Induced Neuronal Apoptosis Through Regulation of BDNF
    Neuropsychopharmacology (2008) 33, 1942–1951 & 2008 Nature Publishing Group All rights reserved 0893-133X/08 $30.00 www.neuropsychopharmacology.org Erythropoietin Prevents Haloperidol Treatment-Induced Neuronal Apoptosis through Regulation of BDNF ,1,2 3 1,2 4 Anilkumar Pillai* , Krishnan M Dhandapani , Bindu A Pillai , Alvin V Terry Jr and 1,2 Sahebarao P Mahadik 1 2 Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA, USA; Medical Research Service Line, Veterans Affairs 3 4 Medical Center, Augusta, GA, USA; Department of Neurosurgery, Medical College of Georgia, Augusta, GA, USA; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, GA, USA Functional alterations in the neurotrophin, brain-derived neurotrophic factor (BDNF) have recently been implicated in the pathophysiology of schizophrenia. Furthermore, animal studies have indicated that several antipsychotic drugs have time-dependent (and differential) effects on BDNF levels in the brain. For example, our previous studies in rats indicated that chronic treatment with the conventional antipsychotic, haloperidol, was associated with decreases in BDNF (and other neurotrophins) in the brain as well as deficits in cognitive function (an especially important consideration for the therapeutics of schizophrenia). Additional studies indicate that haloperidol has other deleterious effects on the brain (eg increased apoptosis). Despite such limitations, haloperidol remains one of the more commonly prescribed antipsychotic agents worldwide due to its efficacy for the positive symptoms of schizophrenia and its low cost. Interestingly, the hematopoietic hormone, erythropoietin, in its recombinant human form rhEPO has been reported to increase the expression of BDNF in neuronal tissues and to have neuroprotective effects.
    [Show full text]
  • Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients with Acute Myeloid Leukemia and High Risk
    2014-0076 March 9, 2015 Page 1 Protocol Page Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients with Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome with FLT3-ITD Mutation 2014-0076 Core Protocol Information Short Title Sorafenib Plus 5-Azacitidine initial therapy of patients with AML and high risk MS with FLT3-ITD Mutation Study Chair: Farhad Ravandi-Kashani Additional Contact: Andrea L. Booker Mary Ann Richie Leukemia Protocol Review Group Department: Leukemia Phone: 713-792-7305 Unit: 428 Full Title: Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients with Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome with FLT3-ITD Mutation Protocol Type: Standard Protocol Protocol Phase: Phase II Version Status: Terminated 11/27/2018 Version: 12 Submitted by: Andrea L. Booker--2/23/2017 1:07:00 PM OPR Action: Accepted by: Julie Arevalo -- 3/3/2017 2:39:37 PM Which Committee will review this protocol? The Clinical Research Committee - (CRC) 2014-0076 March 9, 2015 Page 2 Protocol Body Sorafenib plus 5-Azacitidine Initial Therapy – 2014-0076 March 05, 2015 1 Phase II Study Of Sorafenib Plus 5-Azacitidine For The Initial Therapy Of Patients With Acute Myeloid Leukemia And High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation Short Title: Sorafenib Plus 5-Azacitidine initial therapy of patients with AML and high risk MS with FLT3-ITD mutation PI: Farhad Ravandi, MD Professor of Medicine, Department of Leukemia University of Texas – MD Anderson Cancer Center 1 Sorafenib plus 5-Azacitidine Initial Therapy – 2014-0076 March 05, 2015 2 Contents 1.0 Objectives ........................................................................................................................................
    [Show full text]
  • Lab Dept: Hematology Test Name: ERYTHROPOIETIN
    Lab Dept: Hematology Test Name: ERYTHROPOIETIN General Information Lab Order Codes: EPOS Synonyms: Erythropoietin (EPO), Serum CPT Codes: 82668 - Erythropoietin Test Includes: Erythropoietin level reported in mIU/mL. Logistics Test Indications: This test is mainly used for the differential diagnosis of primary and secondary polycythemia and to determine the cause of anemia. In the diagnosis of primary polycythemia (polycythemia rubra vera) due to an uncontrolled increase in the number of erythrocytes carrying high concentrations of oxygen, the EPO level is suppressed. The test is also useful for diagnosis of appropriate secondary polycythemia caused by high-altitude living, pulmonary disease, and tobacco use, which increase EPO levels. In patients with inappropriate secondary polycythemia caused by renal tumors and extrarenal tumors, the EPO level is also increased. Patients with anemia of bone marrow failure, iron deficiency, or thalassemia also have increased EPO levels Lab Testing Sections: Hematology - Sendouts Referred to: Mayo Medical Laboratories (MML Test: EPO) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Daily, 24 hours Turnaround Time: 2 - 4 days, test set up Monday - Saturday Special Instructions: N/A Specimen Specimen Type: Blood Container: SST (Gold, marble or red) tube Draw Volume: 1.8 mL (Minumum: 1.5 mL) blood Processed Volume: 0.6 mL (Minimum: 0.5 mL) serum Collection: Routine blood collection Special Processing: Lab Staff: Centrifuge specimen, aliquot into a screw-capped plastic vial. Store and ship at refrigerated temperatures. Forward promptly. Patient Preparation: None Sample Rejection: Mislabeled or unlabeled specimen; gross hemolysis Interpretive Reference Range: 2.6 – 18.5 mIU/mL Interpretation: In the appropriate clinical setting (eg, confirmed elevation of hemoglobin >18.5 gm/dL, persistent leukocytosis, persistent thrombocystosis, unusual thrombosis, splenomegaly, and erythromegaly), polycythemia vera is unlikely when EPO levels are elevated and polycythemia vera is likely when EPO levels are suppressed.
    [Show full text]